Related by context. All words. (Click for frequent words.) 81 Cell Lymphoma 80 Cutaneous T 77 Relapsed Refractory 77 Refractory Hodgkin Lymphoma 75 Soft Tissue Sarcoma 75 Leukemias 74 Relapsed 74 Epratuzumab 74 metastatic malignant 73 Pharmacokinetics PK 73 Fludarabine 73 Antigen Specific 73 Chronic Lymphocytic Leukemia 73 Oral Fingolimod 73 Follicular Lymphoma 73 Hormone Refractory Prostate Cancer 73 Phase 2b Clinical Trial 73 leukemia AML 72 Chronic Hepatitis C 72 Antitumor Activity 72 CYT# potent vascular disrupting 72 Renal Cell Carcinoma 72 Anti Tumor Activity 72 Myelofibrosis 72 Myelodysplastic Syndrome MDS 72 Meets Primary Endpoint 72 Malignant Melanoma 72 Metastatic Colorectal Cancer 72 Advanced Renal Cell 72 Chronic Lymphocytic Leukemia CLL 72 Newly Diagnosed Multiple Myeloma 72 dasatinib Sprycel ® 72 small lymphocytic lymphoma 72 Patients Treated With 72 leukemia CLL 72 Phase 2b Study 72 Chronic Myeloid Leukemia 72 Improves Outcomes 71 Castration Resistant Prostate Cancer 71 Novel Oral 71 ara C 71 Targeted Therapy 71 Adjuvant Treatment 71 Mouse Model 71 systemic anaplastic large 71 refractory NSCLC 71 Anti Tumor 71 Relapsing Remitting Multiple Sclerosis 71 Previously Untreated 71 Pooled Analysis 71 Hsp# Inhibitor 71 Glioblastoma Multiforme 71 Improves Survival 71 imatinib Gleevec ® 71 Omacetaxine 71 Prolongs Survival 71 Severe Sepsis 71 Monotherapy 71 Myelodysplastic Syndromes 71 receptor tyrosine kinase inhibitor 70 galiximab 70 Advanced Melanoma 70 Previously Treated 70 Trial Evaluating 70 Patients Receiving 70 Metastatic Renal Cell Carcinoma 70 HDAC Inhibitor 70 Progenitor Cells 70 Multiple Myeloma MM 70 Tyrosine Kinase Inhibitor 70 cell lymphoma CTCL 70 Refractory Peripheral T 70 Relapsing Multiple Sclerosis 70 Aurora Kinase 70 complement inhibitor eculizumab 70 Decitabine 70 essential thrombocythemia ET 70 sunitinib Sutent ® 70 Squamous 70 Ofatumumab 70 Peginterferon 70 previously untreated follicular 70 Anthracycline 70 Adjuvant Chemotherapy 70 multiple myeloma MM 70 Metastatic Melanoma 70 demonstrated antitumor activity 70 Chronic Myelogenous Leukemia 70 Complicated Skin 69 Mantle Cell Lymphoma 69 refractory chronic lymphocytic 69 Elderly Patients 69 Myeloid 69 Peginterferon Alfa 2a 69 pan HDAC inhibitor 69 relapsed MM 69 Preclinical Data 69 Enzastaurin 69 Malignant Glioma 69 Unresectable 69 Bosutinib 69 Pralatrexate 69 Gleevec resistant 69 erlotinib Tarceva ® 69 Cytotoxic T 69 Orally Active 69 Nilotinib 69 TO AVOID PREGNANCY WHILE 69 Myelodysplastic Syndrome 69 Atypical Hemolytic Uremic Syndrome 69 Fluorouracil 69 B Cell Lymphoma 69 Study Evaluating 69 advanced metastatic renal 69 familial amyloidotic polyneuropathy FAP 69 Vidaza ® 69 Ribavirin causes 69 refractory cutaneous T 69 Voreloxin 69 monocytic 69 Well Tolerated 69 Personalized Immunotherapy 69 Adjuvant Therapy 69 Sipuleucel T 69 PEGylated Fab fragment 69 Factor Receptor 69 Survival Benefit 69 Philadelphia Chromosome Positive 69 Solid Tumors 69 ® lenalidomide 69 SSc 69 selective modulator 69 Pegylated 69 imatinib resistant 69 Progressive Multifocal Leukoencephalopathy 69 Kinase Inhibitor 69 Hormone Receptor Positive 69 Phase IIa Clinical Trial 69 PKC# 69 follicular Non Hodgkin 69 SPRYCEL ® 69 Initiates Clinical Trial 68 papillary renal cell carcinoma 68 Immunomodulatory 68 recurrent glioblastoma multiforme 68 Metastatic Prostate Cancer 68 Relapsed Multiple Myeloma 68 Drug Candidate 68 Pivotal Phase III 68 Secondary Hyperparathyroidism 68 Clinical Trial Results 68 Lenalidomide 68 Tolerability 68 Vascular Disrupting Agent 68 atypical hemolytic uremic syndrome 68 TNF Blockers 68 Receives Orphan Drug Designation 68 Tyrosine Kinase Inhibitors 68 Ibritumomab Tiuxetan 68 Granted Orphan Drug 68 Azacitidine 68 Acute Myeloid Leukemia 68 EGFR HER2 68 thalidomide Thalomid 68 5 FU leucovorin 68 Presents Preclinical Data 68 Inhibits 68 undergoing hematopoietic stem 68 gefitinib Iressa 68 Treated Patients 68 Ph + acute lymphoblastic 68 Is Well Tolerated 68 indolent follicular non 68 acute myeloid 68 Autologous Stem Cell Transplantation 68 Cyclophosphamide 68 Novel Inhibitor 68 TNF Tumor Necrosis Factor 68 Ischemic 68 Naive Patients 68 Statistically Significant 68 fosbretabulin 68 II Clinical Trial 68 estramustine 68 Plus Ribavirin 68 Patients Treated 68 Tumor Necrosis Factor 68 Epidermal Growth Factor Receptor 68 Prospective Randomized 68 Pathway Inhibitor 68 Plaque Psoriasis 68 R lenalidomide 68 Phase 2b Trial 68 Diabetic Nephropathy 68 Combination REOLYSIN R 68 Romidepsin 68 Demonstrates Positive 68 Long Term Efficacy 68 Sapacitabine 68 Adjunctive Therapy 68 azacytidine 68 cisplatin resistant 68 Aflibercept 68 CLL SLL 68 RNAi Therapeutic 68 HER2 Positive Breast Cancer 67 R Saizen R 67 Randomized Phase II 67 Pivotal Study 67 Carcinomas 67 Vidaza azacitidine 67 Chronic Sinusitis 67 triggers apoptosis programmed 67 Relapsed Refractory Multiple Myeloma 67 Pegylated Liposomal Doxorubicin 67 Pegylated Interferon 67 myelofibrosis polycythemia vera 67 cisplatin gemcitabine 67 Initiate Phase 67 Disease Progression 67 refractory acute myeloid 67 5 Fluorouracil 67 Phase IIb Trial 67 lymphoid malignancies 67 myelodysplastic myeloproliferative diseases 67 Prophylactic Treatment 67 metastatic GIST 67 NS5B polymerase 67 histological subtype 67 dasatinib Sprycel 67 Investigational Treatment 67 atypical Hemolytic Uremic Syndrome 67 Prognostic Significance 67 Receptor Antagonist 67 Capecitabine 67 Bortezomib 67 Immune Responses 67 Improved Survival 67 colorectal carcinoma 67 Chemotherapy Induced 67 arginine vasopressin AVP 67 Inhaled Corticosteroids 67 Toxicities 67 HLA DR4 67 interferon beta 1a infertility 67 JAK2 V#F 67 Demonstrates Efficacy 67 Predict Response 67 Neovascular Age Related Macular 67 5 fluorouracil leucovorin 67 Eculizumab 67 cutaneous T 67 monoclonal antibody conjugated 67 Relapsed Refractory Aggressive 67 GRNOPC1 contains 67 Metastases 67 Idiopathic Pulmonary Fibrosis 67 haematologic 67 colon carcinoma 67 sunitinib Sutent 67 erythematosus 67 T Cell Lymphoma 67 Squamous Cell Carcinoma 67 Non Hodgkin 67 Nucleoside 67 Hypercholesterolemia 67 metastatic neuroendocrine tumors 67 Pemetrexed 67 topoisomerase II inhibitor 67 accumulate preferentially 67 NMIBC 67 poly ADP ribose polymerase 67 ovarian carcinoma 67 CML CP 67 alkylating agent 67 Lupus Nephritis 67 docetaxel Taxotere ® 67 Carcinoma 67 Primary Hypercholesterolemia 67 neutropenia dehydration dyspnea 67 nonmetastatic 67 Mouse Models 67 pan histone deacetylase 67 Shows Promise Against 67 chronic myeloid 67 Albuferon TM 67 Dose Ranging Study 67 EGFR mutation positive 67 Preclinical Study 67 Metastatic 67 Sustained Efficacy 67 HER2 overexpression 67 orally administered inhibitor 67 Pivotal Phase 67 hypereosinophilic syndrome 67 Anti VEGF 67 MGd 67 prostate carcinoma 67 imatinib Gleevec 67 K ras mutations 67 Hodgkin lymphoma HL 67 Investigational Drug 67 bevacizumab Avastin R 67 cyclophosphamide methotrexate 66 Endometrial 66 novel VDA molecule 66 Akt activation 66 Myeloma Patients 66 metastatic pancreatic 66 CVP cyclophosphamide vincristine 66 metastatic colorectal 66 huN# DM1 66 relapsed refractory multiple myeloma 66 follicular lymphoma FL 66 Completes Patient Enrollment 66 dependent kinase inhibitor 66 Macrophage 66 myeloproliferative diseases 66 Blinatumomab 66 Cardiotoxicity 66 ritonavir boosted 66 Brentuximab Vedotin SGN 66 Chronic HCV 66 LHRH receptor positive 66 Chemoradiation 66 Dose Escalation 66 JAK2 Inhibitor 66 FUSILEV enhances 66 CYP#A# CYP#D# 66 Teriflunomide 66 Pharmacokinetic Study 66 Bevacizumab 66 ZACTIMA 66 Humanized Anti 66 Combination Treatment 66 Hodgkin lymphoma NHL 66 Dose Escalation Study 66 Lymphocytic 66 substantially excreted 66 Acute Ischemic Stroke 66 Gastrointestinal Stromal Tumors 66 Randomized Double blind 66 alfa 2a 66 Unstable Angina 66 tumors GIST 66 Darinaparsin 66 Romiplostim 66 Deforolimus 66 Paclitaxel Carboplatin 66 erythematosus SLE 66 hypertrichosis occurred 66 Antiangiogenic 66 polycythemia vera PV 66 Xanafide 66 chronic eosinophilic leukemia 66 gastrointestinal stromal tumor GIST 66 Combo Therapy 66 Patients Undergoing 66 Skeletal Muscle 66 Occlusive Disease 66 Preclinical Models 66 Antiviral Activity 66 Paraplatin ® 66 IgG1 monoclonal antibody 66 Polymerase Inhibitor 66 Tumor Response 66 EGFR TKI 66 vinca alkaloid 66 Invasive Breast Cancer 66 Rheumatoid Arthritis Patients 66 Non Alcoholic Steatohepatitis 66 Safinamide 66 interleukin IL -# 66 induce orthostatic hypotension 66 Kinase Inhibitors 66 unresectable tumors 66 Hepatocellular Carcinoma 66 Initiates Clinical 66 Cell Lymphoma CTCL 66 induces apoptosis 66 Infected Patients 66 severe neutropenia 66 MAGE A3 ASCI 66 Renal Impairment 66 Septic Shock 66 Chronic Renal Failure 66 relapsed refractory 66 LymphoStat B belimumab 66 stage IIIB 66 Lymphoid 66 adriamycin 66 Antitumor activity 66 ST Elevation Myocardial 66 Pediatric Patients 66 Monoclonal Antibody 66 Initiate Clinical Trial 66 tumor lysis syndrome 66 cancer mCRC 66 Hematologic 66 Controlled Trial 66 epithelial tumors 66 Enzyme Replacement Therapy 66 Etiology 66 myocardial infarction ventricular fibrillation 66 nilotinib Tasigna ® 66 Treatment Naive Patients 66 stage IIIb IV 66 Platinol ® 66 EGFr 66 Treatment Experienced 66 Follicular 66 Myocardial Ischemia 66 Cell Non Hodgkin 66 Interferon Beta 66 ON #.Na 66 Hypertensive Patients 66 tumor xenograft models 66 Randomized Phase 66 Disease Modifying 66 Phase IIb Clinical Trial 66 PEGylated anti 66 kidney urologic 66 lymphocytic leukemia 66 Shows Promising 66 EGFr expressing metastatic colorectal 66 Telaprevir VX 66 generation purine nucleoside 66 FEMALES SHOULD BE ADVISED 66 Cytarabine 65 CDK inhibitor 65 achieved CCyR 65 Advanced Solid Tumors 65 irinotecan containing 65 investigational oral inhibitor 65 irreversible inhibitor 65 Phase 2a Clinical Trial 65 Modulates 65 Acute Myelogenous Leukemia 65 relapsed Acute Myeloid 65 IMiDs ® 65 Dendritic Cells 65 Randomized Double Blind 65 Selective Inhibitor 65 Protease Inhibitor 65 Placebo Controlled Trial 65 gemcitabine carboplatin 65 essential thrombocythemia 65 Advanced Colorectal Cancer 65 Shows Efficacy 65 epithelioid 65 Receptor Antagonists 65 Initiates Enrollment 65 Demonstrates Potential 65 Cytotoxic 65 VEGFR2 inhibitor 65 Cloretazine 65 Induces Apoptosis 65 castrate resistant prostate cancer 65 Seliciclib 65 Spectrum Pharmaceuticals Announces 65 selectively inhibited 65 CHOP chemotherapy 65 CYP#A# substrate 65 mouse xenograft models 65 GW# [003] 65 Achieves Primary Endpoint 65 Newly Diagnosed Patients 65 Advanced Prostate Cancer 65 Controlled Study 65 NCCN Updates 65 HCV Genotype 65 Liver Metastases 65 Improve Survival 65 Kinoid 65 Elotuzumab 65 Investigational Compound 65 Files IND 65 T#I [002] 65 rituximab refractory 65 Leukemia AML 65 Peginterferon Alfa 2b 65 Drug Resistant 65 Phase III Clinical Trial 65 HCV Protease Inhibitor 65 NS5b 65 idiopathic thrombocytopenic purpura ITP 65 Multiple Myeloma Patients 65 recurrent NSCLC 65 Bone Metastases 65 Phase 2a Trial 65 Collaborators Present 65 ® bortezomib 65 ISTODAX ® 65 selective antagonist 65 Papillary 65 Completes Enrollment 65 Systemic lupus erythematosus SLE 65 PEGylated interferon beta 1a 65 BARACLUDE ® 65 demethylating agent 65 Recurrent Glioblastoma 65 lactate dehydrogenase LDH 65 Allogeneic 65 Successfully Completes Phase 65 CD# CD# 65 Overactive Bladder 65 NS#/#A protease 65 potentially hepatotoxic 65 Acute Myeloid Leukemia AML 65 Present Preclinical Data 65 leucopenia 65 JAK Inhibitor 65 Kit CD# positive 65 oral prodrug 65 Upregulation 65 cytopenias 65 Golimumab 65 Alemtuzumab 65 alpha folate receptor 65 Initiates Phase II 65 Novel Treatments 65 autoantibody positive 65 Diabetic Neuropathy 65 Unfractionated Heparin 65 Trastuzumab 65 Presents Positive 65 plus gemcitabine 65 INSPIRE Trial Phase III 65 alefacept 65 Novel Mechanism 65 mediated apoptosis 65 Subgroup Analysis 65 gastrointestinal stromal tumors GISTs 65 topically administered 65 beta 1a 65 Placebo Controlled Study 65 trastuzumab Herceptin R 65 Initiates Phase 65 2 methoxyestradiol 65 Hypertrophy 65 Ozarelix 65 Ischemic Stroke 65 cetuximab Erbitux R 65 Novel Compound 65 Diabetic Foot Ulcer 65 Chronic Heart Failure 65 biliary tract cancer 65 polyglutamate 65 Amgen Neulasta R 65 hA# 65 Obatoclax 65 Neoadjuvant 65 including cyclosporine methotrexate 65 Mg Usa 65 EGFR expressing 65 Hepatic Encephalopathy 65 Tanespimycin 65 Vicriviroc 65 R Bortezomib 65 Doxil ® 65 carcinoma mCRC 65 severe oral mucositis 65 PsA 65 Treatment Reduces 65 gastrointestinal stromal tumors GIST 65 Recombinant Human 65 AVASTIN 65 BRAF V#E 65 SNT-MC#/idebenone 65 Advanced Pancreatic Cancer 65 Peginterferon alfa 2b 65 Polymorphisms 65 HER2 positive metastatic breast 65 mitoxantrone plus 65 xenograft models 65 Retreatment 65 Angioedema 65 PEG IFN 65 metastatic colorectal carcinoma 65 evaluating tivozanib 65 Clinical Outcome 65 Metastatic Pancreatic Cancer 65 Mutational 65 metastatic gastric 65 Fungal Infections 65 Hematological Malignancies 65 Phase III Trial 65 CD# expressing 65 acute humoral rejection 65 Proteasome 65 Amrubicin 65 PAOD 65 Signaling Pathway 65 IMiDs R 65 polycythemia vera essential thrombocythemia 65 D aspartate NMDA receptor 65 Nodular 65 urothelial carcinoma 65 Sudhir Agrawal D.Phil 65 underlying vasculopathy 65 Polyneuropathy 65 immune thrombocytopenic purpura 65 lenalidomide Revlimid R 65 vWF 65 Introgen ADVEXIN 65 Appears Safe 65 bone marrow reticulin deposition 65 Dasatinib 65 denileukin diftitox 65 Chemotherapy Improves 65 investigational humanized monoclonal antibody 65 Investigational Agent 65 cervical lymph nodes 65 cell carcinoma RCC 65 Thrombocytopenia 65 panobinostat 65 Juvenile Idiopathic Arthritis 65 Cytotoxicity 65 Orally administered 65 Hepatocellular 65 Lacosamide 65 Oral Mucositis 65 bevacizumab Avastin ® 65 Gene Mutation 64 PI3K/Akt pathway inhibitor 64 Onyx Pharmaceuticals Announces 64 ANCA associated 64 relapsed leukemia 64 baseline LDH 64 sarcoma melanoma 64 Radiofrequency Ablation 64 Prostatic 64 RECIST Response Evaluation Criteria 64 Fondaparinux 64 factor TNF 64 novel emulsion formulation 64 Intracerebral Hemorrhage 64 Cytochrome P# 64 cisplatin chemotherapy 64 Granulocyte Colony Stimulating Factor 64 Begins Dosing 64 TRAIL induced apoptosis 64 Allogeneic Stem 64 targeted radiotherapeutic 64 Hepatocellular Carcinoma HCC 64 mRCC 64 AAG geldanamycin analog 64 First Patient Dosed 64 Apoptotic 64 targeting CD# 64 Etanercept 64 Nebulized 64 endometrioid 64 myeloid metaplasia 64 irinotecan doxorubicin oxaliplatin paclitaxel 64 Adenomas 64 R roscovitine CDK cyclin 64 Potent Anti 64 MKC# MT 64 Lung Cancers 64 sodium glucose cotransporter 64 Androgen Deprivation Therapy 64 cilengitide 64 Demonstrates Significant 64 Resistant Hypertension 64 pathophysiological effects 64 HGS ETR2 64 Endothelial 64 Glufosfamide 64 hepatoma 64 sarcomatoid 64 Known hypersensitivity 64 Thromboembolism 64 Postmenopausal Women 64 Aliskiren 64 FOLFOX6 64 antigen CD# 64 Solid Tumor 64 antibody MT# 64 chronic idiopathic 64 Xenografts 64 PNP inhibitor 64 Brain Metastases 64 ribavirin Copegus ® 64 Radioimmunotherapy 64 candidates Azedra TM 64 Epithelial 64 Subtypes 64 Lymphomas 64 Platinol ® cisplatin 64 haematologic malignancies 64 histone deacetylase HDAC inhibitor 64 Solid Tumors criteria 64 FOLFOX chemotherapy 64 IN PATIENTS WITH 64 HER2 Positive 64 leukemia APL 64 Beta Amyloid 64 relapsed multiple myeloma 64 metastatic renal cell carcinoma 64 Efficacy Trial 64 receiving VELCADE 64 non nucleoside inhibitor 64 EGFR tyrosine kinase inhibitor 64 Anaplastic 64 non Hodgkin lymphomas 64 hyperphenylalaninemia HPA due 64 Left Ventricular 64 Parkinson disease levodopa induced 64 FDA Okays 64 GMX# 64 AKT inhibitor 64 myeloproliferative 64 Diabetic Neuropathic Pain 64 Glioma 64 mTOR mammalian target 64 ErbB2 positive 64 Archexin 64 idiopathic thrombocytopenic purpura 64 MabCampath 64 HBeAg negative 64 indolent NHL 64 Janus kinase 64 Virulizin ® 64 Friedreich Ataxia FRDA 64 Picoplatin Efficacy After 64 Hypotension 64 Initiate Phase III 64 lymphomas leukemias 64 IAP inhibitor 64 Cyclooxygenase 2 64 Systemic Delivery 64 mapatumumab 64 Posaconazole 64 Treatment Naïve 64 ZOLINZA 64 8mg/kg 64 Colorectal Cancer Patients 64 Renal Cell Cancer 64 androgen independent 64 malignant ascites 64 Estrogen Receptor 64 alkylating 64 huC# DM4 64 Drug Shows Promise 64 mucinous 64 Chronic Myelogenous Leukemia CML 64 Pivotal Trial 64 Adenocarcinoma 64 selective phosphodiesterase 64 ptau 64 Newly Diagnosed 64 Neutrophil 64 DOXIL 64 Induction Therapy 64 chronic immune thrombocytopenic 64 allogeneic bone marrow 64 generation antisense inhibitor 64 Rituximab 64 mediated inhibition 64 aplastic anemia AA 64 pralatrexate injection folate analogue 64 FOLOTYN ® 64 Drug Prevents 64 Vincristine 64 AML MDS 64 Combination Therapy 64 Chronic lymphocytic leukemia CLL 64 Fast Track Status 64 Bronchiectasis 64 Fibroblast 64 Circulating Tumor Cells 64 Mitomycin C 64 Pulmonary Arterial Hypertension 64 Successfully Treated 64 B Cell Malignancies 64 Isavuconazole 64 Renal Artery 64 Acute Myelogenous Leukemia AML 64 hematological parameters 64 Shows Statistically Significant 64 Adenoviral 64 Irinotecan 64 IL# PE#QQR 64 vapreotide acetate 64 hepatocellular carcinomas 64 Folfox 64 Hepatitis C Genotype 64 anemia thrombocytopenia 64 treat benign prostatic 64 Potent Inhibitor 64 Annamycin 64 vincristine doxorubicin 64 LPS induced 64 Amgen Neulasta ® 64 oropharyngeal candidiasis OPC 64 Acute myeloid leukemia 64 VELCADE melphalan 64 aspartate aminotransferase AST 64 Tumor Growth 64 Autoimmune Disorders 64 DLBCL 64 fallopian tube carcinoma 64 Carfilzomib 64 M2 subunit 64 unresectable stage 64 Single Dose 64 Clostridium difficile Infection 64 Node Positive 64 ERK1 2 64 Demonstrated Significant 64 antibody MAb 64 Induces 64 Clinical Trial Evaluating 64 CTAP# Capsules 64 FOLFOX6 chemotherapy regimen 64 IND Application 64 thymoma 64 gastrointestinal stromal tumor 64 imatinib resistance 64 Critically Ill Patients 64 acute GvHD 64 pulmonary metastases 64 Treatment Resistant 64 Hemolysis 64 Neoadjuvant Chemotherapy 64 5alpha reductase 64 XL# inhibits 64 Xeloda ® 64 chronic lymphocytic 64 IMiDs ® compound 64 relapsing remitting MS RRMS 64 Aeolus Pharmaceuticals Announces 64 Acute myeloid leukemia AML 64 lymphoproliferative disorder 64 gastric carcinoma 64 adalimumab Humira 64 Paroxysmal Nocturnal Hemoglobinuria PNH 64 Study Demonstrates 64 protein tyrosine phosphatase 1B 64 unique alkylating agent 64 Acute Myocardial Infarction 64 INCB# [003] 64 bortezomib refractory 64 Gene Linked 64 Heterozygous Familial Hypercholesterolemia 64 Degarelix 64 taxane resistant 64 gemcitabine Gemzar ® 64 Endometrial Cancer 63 Vitro Activity 63 Slow Progression 63 non splenectomized 63 lung pancreatic 63 Seasonal Allergic Rhinitis 63 proteasome inhibitor 63 Temsirolimus 63 renal carcinoma 63 plasma kallikrein inhibitor 63 HLA DR2 63 trial evaluating PRX# 63 Tubulin 63 Melphalan 63 Antitumor 63 NSCLC tumors 63 Increased Mortality 63 COPEGUS R 63 vWD 63 TRAIL R1 63 PRN FDA Approves 63 Basal Cell 63 corticosteroid dexamethasone 63 elevated transaminases 63 NDA Submission 63 pancreatic adenocarcinoma 63 Acute Renal Failure 63 induced apoptosis 63 developing Bicifadine serotonin 63 Viral Load 63 Attenuates 63 metastatic castration resistant 63 Mg Uk 63 Zorbtive TM 63 administered concomitantly 63 Exacerbation 63 Neutropenia 63 Acute Exacerbations 63 Transdermal Patch 63 Chronic Hepatitis B 63 MCSP respectively 63 Patients Suffering 63 evaluating picoplatin 63 MEK Inhibitor 63 APOPTONE 63 Physician Insights 63 transthyretin amyloidosis 63 cortisol synthesis 63 CTAP# 63 mycosis fungoides 63 Breast Cancer Recurrence 63 Autoantibodies 63 Fulvestrant 63 dual endothelin receptor antagonist 63 fluvastatin 63 lung carcinomas 63 Contralateral 63 selective inverse agonist 63 Rheumatoid Arthritis RA 63 myeloproliferative disorders 63 Systemic Sclerosis 63 Daclizumab 63 chimeric monoclonal antibody 63 Demonstrate Significant 63 paragangliomas 63 Adjunctive 63 purpura ITP 63 Interferon gamma 63 Sevelamer 63 deletion 5q 63 ALB # 63 Gastric Cancer 63 Non Alcoholic Fatty 63 idiopathic membranous nephropathy 63 Maribavir 63 cis retinoic acid 63 molecule epidermal 63 Protein Kinase C 63 cholangiocarcinoma 63 Renal dysfunction 63 Hedgehog Pathway 63 intravesical infusion therapy 63 refractory indolent non 63 Demonstrates Potent 63 Fludara ® 63 antiproliferative effects 63 NASH Huntington 63 Dose Finding 63 Radiofrequency Ablation RFA 63 Neuroendocrine Tumors 63 Placebo Controlled 63 Chronic Myeloid Leukemia CML 63 Reperfusion Injury 63 sorafenib tablets 63 occlusion PAO 63 urothelial 63 inducible nitric oxide synthase 63 syngeneic 63 uricase 63 pancreatic carcinoma 63 abacavir Ziagen 63 hepatorenal syndrome 63 myeloproliferative neoplasms 63 hormone refractory metastatic prostate 63 situ CIS 63 Aplidin R 63 colorectal adenocarcinoma 63 Sustained Virologic Response 63 pDC 63 included exfoliative dermatitis 63 peripheral blood mononuclear 63 Patient Outcomes 63 nucleoside analog 63 Tyrosine Kinase 63 p# mitogen activated 63 Genes Predict 63 keloid scarring 63 bleomycin 63 Vidofludimus 63 Prostate Cancer Progression 63 Meta Analysis 63 acute leukemias 63 Hurthle cell 63 follicular CD# positive 63 pediatric Crohn disease 63 Inflammatory Markers 63 Diabetic Patients 63 gemcitabine Gemzar 63 oral Janus kinase 63 Thromboembolic 63 Gemzar ® 63 Proves Effective 63 Initiates Phase III 63 mCRC patients 63 HBeAg + 63 hemodynamically significant 63 5q MDS 63 Immunosuppression 63 Pancreatic Adenocarcinoma 63 Genentech Rituxan 63 pancytopenia 63 nutlin 3a 63 receiving INTRON 63 recurrent metastatic ovarian cancer 63 Luminal 63 somatostatin analog 63 intratumoral injection 63 Non Responders 63 Nephrol 63 NOMID